

# A Wolf in Sheep's Clothing: A Mysterious Case of Seizures

Isabel Shore, MD, Weiwei Beckerleg, MD FRCPC and Delvina Hasimja, MD FRCPC  
Ottawa Hospital, Department of Medicine

## Patient Presentation

A 22M with a history of quiescent juvenile arthritis presented to ED in his northern community with arthralgias. He was incidentally found to have mild normocytic anemia and leukopenia, with a slightly elevated creatinine. He was discharged with a plan for further investigations including an autoimmune workup.

**Two weeks later**, he represented with **3 generalized tonic-clonic seizures**.

## Initial Management

**CT Head** showed **ill-defined hypodense lesions in the left frontal lobe, right insula, and left cerebellar hemisphere**. The differential included **metastatic disease and disseminated infection**. MRI brain recommended for further assessment.

He was loaded with Keppra and transferred to tertiary care for ongoing management.

## History and Physical Examination

Assessment in ED revealed the following symptoms over the preceding months:

- Intermittent abdominal and joint pain
- 15 lbs weight loss, anorexia, and occasional night sweats
- Hyperpigmented facial rash
- Alopecia (see Image 1)
- Hyperpigmented lesions on the palmar aspects of his hands (see Image 2)





Image 1. Hand lesions



Image 2. Alopecia

## Further Investigations



**MRI Brain (T2 FLAIR images above):** Multiple hemorrhagic lesions. **Etiology unclear, cannot exclude underlying mass lesion or septic infarct.**

### Laboratory findings:

WBC 4.7, Hb 83 (MCV 95.5), Plat 285  
Electrolytes N, **Cr 148**

**BCx x2 negative. LP negative.**

CRP 37.5, ESR 60

**ANA 1:2560 (speckled), dsDNA >667**  
**C3 0.46, C4 0.05**

ENA +, Anti-Sm > 694, RNP > 664, SSA > 1,375  
Cardiolipins +, B2 glycoprotein, and LA negative  
RF 29, CCP < 5, ANCA negative

**TTE/TEE negative for thrombus/IE**

## Diagnosis

**Final Dx:** Systemic lupus erythematosus with neuropsychiatric involvement (vasculitis), bicytopenia, dermatologic manifestations, and arthritis. Renal biopsy later confirmed grade 2-3 lupus nephritis.

Patient was started on hydroxychloroquine, steroids, and Rituximab.

## Discussion

**Neuropsychiatric SLE (NPSLE) describes the CNS manifestations of lupus.**

- Heterogeneous group including psychiatric presentations, seizures, and strokes. The ACR has defined 19 distinct NPSLE syndromes.<sup>1</sup>
  - Prevalence varies significantly; some studies estimate NPSLE occurs in **40-50% of patients with ranges from 12-95% described.**<sup>4</sup>
  - NPSLE is a major source of morbidity and mortality in SLE.<sup>2</sup>
  - Pathophysiology is complex; suspected to involve microvasculopathy and neurotoxicity due to cytokines, autoantibodies, and immune complexes.<sup>2</sup>
  - Diagnosis is based on clinical assessment, serologies, and imaging (MRI preferred).<sup>4</sup>
- Management is challenging:**
- Foundation is symptomatic management, especially in mild cases (ie. Antipsychotics, antiepileptics).<sup>1</sup>
  - Immunosuppression with corticosteroids, azathioprine, cyclophosphamide, and mycophenolate is often required. IVIG and rituximab have been used in cases unresponsive to steroids or cytotoxic therapies.<sup>3</sup>

## LEARNING OBJECTIVES

- 1) Recognize CNS manifestations of SLE, including vasculitis and seizure
- 2) Review the pathophysiology, epidemiology, and management of neuropsychiatric SLE

## REFERENCES

- (1) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. (1999). *Arthritis and rheumatism*, 42(4), 599–608. doi: [10.1002/1529-0131\(199904\)42:4<599::AID-ANR2>3.0.CO;2-F](https://doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F)
- (2) Schwartz, N., Stock, A. D., & Putterman, C. (2019). Neuropsychiatric lupus: new mechanistic insights and future treatment directions. *Nature reviews. Rheumatology*, 15(3), 137–152. <https://doi.org/10.1038/s41584-018-0156-8>.
- (3) Popescu, A., & Kao, A. H. (2011). Neuropsychiatric systemic lupus erythematosus. *Current neuropharmacology*, 9(3), 449–457. <https://doi.org/10.2174/157015911796557984>.
- (4) Sarwar, S., Mohamed, A. S., Rogers, S., Sarmast, S. T., Kataria, S., Mohamed, K. H., Khalid, M. Z., Saeeduddin, M. O., Shiza, S. T., Ahmad, S., Awais, A., & Singh, R. (2021). Neuropsychiatric Systemic Lupus Erythematosus: A 2021 Update on Diagnosis, Management, and Current Challenges. *Cureus*, 13(9), e17969. <https://doi.org/10.7759/cureus.17969>.

## CONFLICTS OF INTEREST

Co-Author	Conflict disclosures
Isabel Shore	None
Weiwei Beckerleg	None
Delvina Hasimja	None